Theriva Biologics (TOVX) Q4 2025 earnings summary

Executive summary

• Advanced VCN-01 clinical development for pancreatic ductal adenocarcinoma (PDAC) and retinoblastoma, with regulatory feedback from EMA and planned FDA meetings in 2026.

• Licensed SYN-020 to Rasayana Therapeutics, securing up to $38 million in milestones and royalties.

• Cash position increased to $15.2 million as of February 26, 2026, providing runway into Q1 2027.

Financial highlights

• Cash and cash equivalents were $13.1 million at December 31, 2025, up from $11.6 million at December 31, 2024.

• General and administrative expenses rose 109% year-over-year to $15.4 million, mainly due to a $9.0 million contingent consideration adjustment.

• Research and development expenses decreased 28% year-over-year to $8.6 million, reflecting lower clinical trial costs.

• Net loss for 2025 was $23.7 million, compared to $25.7 million in 2024.

• Total assets increased to $38.2 million at year-end 2025 from $35.4 million in 2024.

Outlook and guidance

• Cash runway expected to fund operations into Q1 2027, supporting ongoing and planned clinical and regulatory activities.

• Research and development expenses anticipated to decrease in 2026 due to workforce reduction and completion of major trials.

• Focus remains on advancing VCN-01 pivotal trials and supporting preclinical pipeline.